• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Recurrence rates of treated basal cell carcinomas. Part 1: Overview.

作者信息

Silverman M K, Kopf A W, Grin C M, Bart R S, Levenstein M J

机构信息

Department of Dermatology, New York University School of Medicine, New York.

出版信息

J Dermatol Surg Oncol. 1991 Sep;17(9):713-8. doi: 10.1111/j.1524-4725.1991.tb03424.x.

DOI:10.1111/j.1524-4725.1991.tb03424.x
PMID:1890243
Abstract

This is the first article in a series reviewing the extensive experience of the Oncology Section of the Skin and Cancer Unit, from 1955 through 1982, with 5755 basal cell carcinomas (BCCs) treated by curettage-electrodesiccation, surgical excision, or x-ray therapy. Recurrence rates were calculated by three methods for each of the treatment modalities: 1) by the raw recurrence rate method; 2) by the "strict" 5-year recurrence rate method; and 3) by modification of the life-table method. Our analyses show that the last method best approximates the true recurrence rate. Primary (previously untreated) BCCs had a 5-year recurrence rate of 10.6% (standard error 0.6%), and previously treated BCCs had a rate of 15.4% (standard error 1.3%) (P = .0002). The greatest risk for recurrence of treated primary BCCs occurred 1 to 4 years after therapy. It is concluded that recurrence rates of primary BCCs should be reported separately from those of previously treated BCCs and that the modified life-table method is best suited to calculate 5-year recurrence rates.

摘要

相似文献

1
Recurrence rates of treated basal cell carcinomas. Part 1: Overview.
J Dermatol Surg Oncol. 1991 Sep;17(9):713-8. doi: 10.1111/j.1524-4725.1991.tb03424.x.
2
Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation.
J Dermatol Surg Oncol. 1991 Sep;17(9):720-6. doi: 10.1111/j.1524-4725.1991.tb03425.x.
3
Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy.经治疗的基底细胞癌的复发率。第4部分:X线治疗。
J Dermatol Surg Oncol. 1992 Jul;18(7):549-54. doi: 10.1111/j.1524-4725.1992.tb03508.x.
4
Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision.
J Dermatol Surg Oncol. 1992 Jun;18(6):471-6. doi: 10.1111/j.1524-4725.1992.tb03307.x.
5
Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.刮除术和电干燥法治疗面部高危区域原发性基底细胞癌的复发率
J Am Acad Dermatol. 2007 Jan;56(1):91-5. doi: 10.1016/j.jaad.2006.07.007.
6
Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone.单独用电干燥术和刮除术治疗后侵袭性组织学类型基底细胞癌的复发率。
Dermatol Surg. 2013 May;39(5):719-25. doi: 10.1111/dsu.12122. Epub 2013 Feb 4.
7
A systematic review of treatment modalities for primary basal cell carcinomas.原发性基底细胞癌治疗方式的系统评价
Arch Dermatol. 1999 Oct;135(10):1177-83. doi: 10.1001/archderm.135.10.1177.
8
Whole specimen intraoperative frozen section analysis. Experience with 1082 basal cell carcinomas.全标本术中冰冻切片分析。1082例基底细胞癌的经验。
Eur J Surg Oncol. 2018 Jan;44(1):157-162. doi: 10.1016/j.ejso.2017.11.004. Epub 2017 Nov 23.
9
Multivariate risk score for recurrence of cutaneous basal cell carcinomas.
Arch Dermatol. 1983 May;119(5):373-7.
10
Treatment of basal cell carcinoma of the skin with curettage.
Arch Dermatol. 1971 Jun;103(6):623-7.

引用本文的文献

1
Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin Cancer.影像引导与非黑色素瘤皮肤癌浅表放射治疗后复发率降低相关。
Adv Radiat Oncol. 2024 Feb 9;9(12):101463. doi: 10.1016/j.adro.2024.101463. eCollection 2024 Dec.
2
S2k guideline basal cell carcinoma of the skin (update 2023).S2k皮肤基底细胞癌指南(2023年更新)
J Dtsch Dermatol Ges. 2024 Dec;22(12):1697-1714. doi: 10.1111/ddg.15566. Epub 2024 Nov 25.
3
The State of the Art of Image Guided Superficial Radiation Therapy Treatment of Non-melanoma Skin Cancer in Outpatient Dermatology Clinics in the United States and Review of the Literature.
美国门诊皮肤科诊所非黑色素瘤皮肤癌的图像引导浅表放射治疗现状及文献综述
Oncol Ther. 2025 Mar;13(1):31-48. doi: 10.1007/s40487-024-00310-6. Epub 2024 Nov 21.
4
Review of recent advances in managing periocular skin malignancies.眼周皮肤恶性肿瘤治疗的最新进展综述
Front Oncol. 2024 Mar 4;14:1275930. doi: 10.3389/fonc.2024.1275930. eCollection 2024.
5
The inherent fragility of collective proliferative control.集体增殖控制的内在脆弱性。
bioRxiv. 2024 Aug 19:2024.01.23.576783. doi: 10.1101/2024.01.23.576783.
6
Lymph Node Metastases from Non-Melanoma Skin Cancer of the Head and Neck.头颈部非黑色素瘤皮肤癌的淋巴结转移
Cancers (Basel). 2023 Aug 22;15(17):4201. doi: 10.3390/cancers15174201.
7
Resection of Skin Cancer Resulting in Free Vascularized Tissue Reconstruction: Always a Therapeutic Failure?皮肤癌切除术后行带血管游离组织重建:总是治疗失败吗?
Cancers (Basel). 2023 Apr 25;15(9):2464. doi: 10.3390/cancers15092464.
8
High resolution dermal ultrasound (US) combined with superficial radiation therapy (SRT) versus non-image guided SRT or external beam radiotherapy (XRT) in early-stage epithelial cancer: a comparison of studies.高分辨率皮肤超声(US)联合浅表放射治疗(SRT)与非影像引导 SRT 或外照射放射治疗(XRT)治疗早期上皮癌的研究比较。
BMC Cancer. 2023 Jan 28;23(1):98. doi: 10.1186/s12885-023-10577-z.
9
Superficial high-dose-rate brachytherapy for primary tumors and relapses after surgery in patients with basal cell carcinoma of the head and neck region: results of a retrospective comparative cohort study.头颈部基底细胞癌患者原发性肿瘤及术后复发的浅表高剂量率近距离放射治疗:一项回顾性比较队列研究的结果
J Contemp Brachytherapy. 2022 Oct;14(5):438-445. doi: 10.5114/jcb.2022.121134. Epub 2022 Nov 14.
10
Local control comparison of early-stage non-melanoma skin Cancer (NMSC) treated by superficial radiotherapy (SRT) and external beam radiotherapy (XRT) with and without dermal image guidance: a meta-analysis.采用和不采用皮肤影像引导的浅表放射治疗(SRT)和外照射放疗(XRT)治疗早期非黑色素瘤皮肤癌(NMSC)的局部控制比较:一项荟萃分析。
Discov Oncol. 2022 Nov 21;13(1):129. doi: 10.1007/s12672-022-00593-z.